SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate...
Hence then, the article about immunoforge to showcase proprietary platform technologies and next generation oncology phase 2 clinical pipelines at bio europe 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026 )
Also on site :
- Penn Yan schools on lockdown and lockout due to possible report of weapon at high school
- NBC Extends ‘Line of Fire’ With Full-Season Pickup
- In 1944, Curtis Springer claimed 12,800 acres of Mojave land and built Zzyzx; the government evicted him in 1974